Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,654
archived clinical trials in
Cardiology

Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Waco, TX
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Waco, TX
Click here to add this to my saved trials
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Camp Hill, PA
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Camp Hill, PA
Click here to add this to my saved trials
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated:  12/31/1969
mi
from
Montreal,
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated: 12/31/1969
mi
from
Montreal,
Click here to add this to my saved trials
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Washington,
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Bronx, NY
Investigational Device Exemption Study to Determine the Safety and Efficacy of the Astron and Pulsar Stents
The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar Stents
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Bronx, NY
Click here to add this to my saved trials
A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)
A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Efficacy and Safety of Dalcetrapib on Lipids, Lipoproteins, Apolipoproteins and Markers of Cardiovascular (CV) Risk in Patients Hospitalized for an Acute Coronary Syndrome (ACS) When Treatment is Initiated Within 1 Week After an ACS (Dal-ACUTE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Pensacola, FL
A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)
A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Efficacy and Safety of Dalcetrapib on Lipids, Lipoproteins, Apolipoproteins and Markers of Cardiovascular (CV) Risk in Patients Hospitalized for an Acute Coronary Syndrome (ACS) When Treatment is Initiated Within 1 Week After an ACS (Dal-ACUTE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Pensacola, FL
Click here to add this to my saved trials
A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)
A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Efficacy and Safety of Dalcetrapib on Lipids, Lipoproteins, Apolipoproteins and Markers of Cardiovascular (CV) Risk in Patients Hospitalized for an Acute Coronary Syndrome (ACS) When Treatment is Initiated Within 1 Week After an ACS (Dal-ACUTE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Saginaw, MI
A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)
A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Efficacy and Safety of Dalcetrapib on Lipids, Lipoproteins, Apolipoproteins and Markers of Cardiovascular (CV) Risk in Patients Hospitalized for an Acute Coronary Syndrome (ACS) When Treatment is Initiated Within 1 Week After an ACS (Dal-ACUTE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Saginaw, MI
Click here to add this to my saved trials
A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)
A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Efficacy and Safety of Dalcetrapib on Lipids, Lipoproteins, Apolipoproteins and Markers of Cardiovascular (CV) Risk in Patients Hospitalized for an Acute Coronary Syndrome (ACS) When Treatment is Initiated Within 1 Week After an ACS (Dal-ACUTE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Syracuse, NY
A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)
A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Efficacy and Safety of Dalcetrapib on Lipids, Lipoproteins, Apolipoproteins and Markers of Cardiovascular (CV) Risk in Patients Hospitalized for an Acute Coronary Syndrome (ACS) When Treatment is Initiated Within 1 Week After an ACS (Dal-ACUTE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Syracuse, NY
Click here to add this to my saved trials
A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)
A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Efficacy and Safety of Dalcetrapib on Lipids, Lipoproteins, Apolipoproteins and Markers of Cardiovascular (CV) Risk in Patients Hospitalized for an Acute Coronary Syndrome (ACS) When Treatment is Initiated Within 1 Week After an ACS (Dal-ACUTE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Rapid City, SD
A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)
A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Efficacy and Safety of Dalcetrapib on Lipids, Lipoproteins, Apolipoproteins and Markers of Cardiovascular (CV) Risk in Patients Hospitalized for an Acute Coronary Syndrome (ACS) When Treatment is Initiated Within 1 Week After an ACS (Dal-ACUTE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Rapid City, SD
Click here to add this to my saved trials
A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)
A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Efficacy and Safety of Dalcetrapib on Lipids, Lipoproteins, Apolipoproteins and Markers of Cardiovascular (CV) Risk in Patients Hospitalized for an Acute Coronary Syndrome (ACS) When Treatment is Initiated Within 1 Week After an ACS (Dal-ACUTE)
Status: Enrolling
Updated:  12/31/1969
mi
from
Ceske Budejovice,
A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)
A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Efficacy and Safety of Dalcetrapib on Lipids, Lipoproteins, Apolipoproteins and Markers of Cardiovascular (CV) Risk in Patients Hospitalized for an Acute Coronary Syndrome (ACS) When Treatment is Initiated Within 1 Week After an ACS (Dal-ACUTE)
Status: Enrolling
Updated: 12/31/1969
mi
from
Ceske Budejovice,
Click here to add this to my saved trials
A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)
A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Efficacy and Safety of Dalcetrapib on Lipids, Lipoproteins, Apolipoproteins and Markers of Cardiovascular (CV) Risk in Patients Hospitalized for an Acute Coronary Syndrome (ACS) When Treatment is Initiated Within 1 Week After an ACS (Dal-ACUTE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Saint Cloud, MN
A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)
A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Efficacy and Safety of Dalcetrapib on Lipids, Lipoproteins, Apolipoproteins and Markers of Cardiovascular (CV) Risk in Patients Hospitalized for an Acute Coronary Syndrome (ACS) When Treatment is Initiated Within 1 Week After an ACS (Dal-ACUTE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Saint Cloud, MN
Click here to add this to my saved trials
Phase II Clinical Trial to Evaluate the Benefits of Postconditioning in ST-Elevation Myocardial Infarction (STEMI)
Phase II Clinical Trial to Evaluate the Benefits of Postconditioning in STEMI
Status: Enrolling
Updated:  12/31/1969
Abbott Northwestern Hospital
mi
from
Minneapolis, MN
Phase II Clinical Trial to Evaluate the Benefits of Postconditioning in ST-Elevation Myocardial Infarction (STEMI)
Phase II Clinical Trial to Evaluate the Benefits of Postconditioning in STEMI
Status: Enrolling
Updated: 12/31/1969
Abbott Northwestern Hospital
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Athens, AL
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Athens, AL
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigator Site
mi
from
Birmingham, AL
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigator Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigator Site
mi
from
Birmingham, AL
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigator Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigator Site
mi
from
Birmingham, AL
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigator Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigator Site
mi
from
Birmingham, AL
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigator Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Fairhope, AL
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Fairhope, AL
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Huntsville, AL
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Huntsville, AL
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Mobile, AL
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Mobile, AL
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Mobile, AL
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Mobile, AL
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Mobile, AL
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Mobile, AL
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Mobile, AL
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Mobile, AL
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Anchorage, AK
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Anchorage, AK
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Chandler, AZ
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Chandler, AZ
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigational Site
mi
from
Glendale, AZ
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigational Site
mi
from
Glendale, AZ
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Phoenix, AZ
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Phoenix, AZ
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Phoenix, AZ
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Hot Springs, AR
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Hot Springs, AR
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Jonesboro, AR
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Jonesboro, AR
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Little Rock, AR
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Little Rock, AR
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Little Rock, AR
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Little Rock, AR
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Little Rock, AR
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Little Rock, AR
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Beverly Hills, CA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Carmichael, CA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Carmichael, CA
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Escondido, CA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Escondido, CA
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Fullerton, CA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Fullerton, CA
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Huntington Beach, CA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Huntington Beach, CA
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Huntington Beach, CA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Huntington Beach, CA
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Lancaster, CA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Lancaster, CA
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Loma Linda, CA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Loma Linda, CA
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Loma Linda, CA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Loma Linda, CA
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Long Beach, CA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Long Beach, CA
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Long Beach, CA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Long Beach, CA
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative site
mi
from
Los Angeles, CA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative site
mi
from
Los Angeles, CA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative site
mi
from
Los Angeles, CA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative site
mi
from
Los Angeles, CA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Los Gatos, CA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Los Gatos, CA
Click here to add this to my saved trials